Filing Details
- Accession Number:
- 0001140361-13-039639
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2013-10-28 09:31:38
- Reporting Period:
- 2013-10-24
- Filing Date:
- 2013-10-28
- Accepted Time:
- 2013-10-28 09:31:38
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 874716 | Idexx Laboratories Inc | IDXX | In Vitro & In Vivo Diagnostic Substances (2835) | 010393723 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1184149 | W Jonathan Ayers | One Idexx Drive Westbrook ME 04092 | Chairman, President & Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2013-10-24 | 13,000 | $25.45 | 352,990 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2013-10-24 | 7,000 | $41.94 | 359,990 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2013-10-24 | 25,000 | $50.00 | 384,990 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2013-10-24 | 38,700 | $104.20 | 346,290 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2013-10-24 | 389 | $104.97 | 345,901 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2013-10-25 | 13,000 | $25.45 | 358,901 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2013-10-25 | 7,000 | $41.94 | 365,901 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2013-10-25 | 25,000 | $50.00 | 390,901 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2013-10-25 | 8,255 | $104.30 | 382,646 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2013-10-25 | 30,834 | $104.58 | 351,812 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2013-10-24 | 13,000 | $0.00 | 13,000 | $25.45 |
| Common Stock | Non-Qualifed Stock Option (right to buy) | Disposition | 2013-10-24 | 7,000 | $0.00 | 7,000 | $41.94 |
| Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2013-10-24 | 25,000 | $0.00 | 25,000 | $50.00 |
| Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2013-10-25 | 13,000 | $0.00 | 13,000 | $25.45 |
| Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2013-10-25 | 7,000 | $0.00 | 7,000 | $41.94 |
| Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2013-10-25 | 25,000 | $0.00 | 25,000 | $50.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 93,072 | 2014-02-04 | No | 4 | M | Direct | |
| 50,616 | 2014-02-13 | No | 4 | M | Direct | |
| 175,000 | 2014-02-13 | No | 4 | M | Direct | |
| 80,072 | 2014-02-04 | No | 4 | M | Direct | |
| 43,616 | 2014-02-13 | No | 4 | M | Direct | |
| 150,000 | 2014-02-13 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 49,000 | Indirect | By Ayers Family Trust |
Footnotes
- Includes 66 shares, 68 shares and 68 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on 03/29/2013, 06/28/2014 and 09/30/2013, respectively.
- The sale reported above was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 02/28/2013.
- The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $103.85 to $104.80, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 3, 4, 5 and 6 to this Form 4.
- The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $104.91 to $105.02, inclusive.
- The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $103.48 to $104.475, inclusive.
- The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $104.48 to $104.79, inclusive.
- Grant of options to buy shares of common stock becomes exercisable as to 22,000 shares on 02/05/2005, 02/05/2006, 02/05/2007 and 02/05/2008, and the remaining 18,072 shares on 02/05/2009.
- Grant of options to buy shares of common stock becomes exercisable as to 12,000 shares on 02/14/2008, 02/14/2009, 02/14/2010 and 02/14/2011, and the remaining 9,616 shares on 02/14/2012.
- Grant of options to buy shares of common stock that vest in five equal annual installments, beginning on the first anniversary date(02/14/2008) of the date of grant.
Billionaire Hedge Funds
